128results about How to "Reduce restenosis" patented technology

The present invention provides a catheter balloon, and balloon catheter incorporating the catheter balloon, useful in medical dilation procedures. The catheter balloon includes at least one microscalpel operatively disposed on an outer surface thereof. The microscalpel may advantageously be operatively disposed relative to a power source so as to be controllably activatable. Also provided are methods of making the inventive balloon and / or catheter as well as methods of using the inventive catheter in a dilation / incising treatment.

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.

The present invention provides devices and methods for decalcifying an aortic valve. The methods and devices of the present invention break up or obliterate calcific deposits in and around the aortic valve through application or removal of heat energy from the calcific deposits.

The present invention relates to the use of a gene transfer product to reduce hyperplastic connective tissue growth after tissue trauma or implantation of a medical device. The present invention also relates to a medical device with improved biological properties for an at least partial contact with blood, bodily fluids and / or tissues when introduced in a mammalian body, which device comprises a core and a nucleic acid, encoding a product capable of leading to production of extracellular superoxide dismutase present in a biologically compatible medium. Said nucleic acid encodes a translation or transcription product, which is capable of inhibiting hyperplastic connective tissue growth and promoting endothelialisation in vivo at least partially on a synthetic surface of said core. The present invention also relates to a method of producing a medical device according to the invention.

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent / medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and / or preventing adjacent diseases or maintaining patency of the body lumen.

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent / medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and / or preventing adjacent diseases or maintaining patency of the body lumen.

Devices, systems and methods for treating medical conditions using cell therapy via body lumens. Localized delivery is achieved with the use of a stent-like expandable body seeded with cells. The expandable body is expanded to contact at least a portion of the inner walls of the body lumen and the cells, cellular products and / or other therapeutic agents are delivered to the surrounding tissue. The therapeutic benefit provided is dependent on the type of cells used and the features of the expandable body.

A tissue cutting device includes a catheter with a window at its distal tip for admitting tissue into a catheter compartment. A cylindrical cartridge in the compartment has a cutting edge that supports an electrically conductive cutting element, e.g. a band or wire. The cutting element and adjacent tissue can be heated to a selected temperature by generating an electrical current through the cutting element. The catheter is maneuverable to position its distal end near the tissue to be cut. The catheter incorporates a dilatation balloon or other feature to urge the catheter against the tissue, so that at least part of the tissue may enter the compartment through the window. Then, the cartridge is manipulated from the catheter's proximal end to move the cutting edge across the window, cutting the tissue. According to alternative embodiments, the cartridge is either rotated or moved axially relative to the catheter and, in either event may be capable of closing the catheter window when the cut is complete. Further alternatives involve either placing an indifferent electrode on the patient and providing an RF signal via a single conductor to the cutting element for ohmic heating, or providing an RF (or a DC) current through the cutting element and two separate conductors for direct resistive heating of the cutting element.

The present invention provides devices and methods for decalcifying an aortic valve. The methods and devices of the present invention break up or obliterate calcific deposits in and around the aortic valve through application or removal of heat energy from the calcific deposits.

A stent includes a stent body having a circumference and struts disposed helically about the circumference in turns. At least two of the struts have respective strut ends. At least two paddle-shaped markers extend away from a respective one of the strut ends. The markers have respective marker extreme ends and different overall longitudinal lengths substantially aligning the marker extreme ends approximately along a single circumference of the stent body. A method for manufacturing a helical stent includes the steps of providing a stent body with struts disposed about the circumference thereof in turns and with bridges connecting the struts in adjacent turns. The stent body is expanded and, thereafter, some of the bridges, in particular, sacrificial bridges, are removed.

An expandable stent is provided, wherein the stent is advantageously formed of at least one amorphous metal alloy and a biocompatible material. The stent is formed from flat metal in a helical strip which is wound to form a tubular structure. The tubular structure is not welded but rather is wrapped or coated with a biocompatible material in order to maintain the amorphous metal in its tubular configuration. Said stent can be balloon expanded or self expanding.

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent / medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and / or preventing adjacent diseases or maintaining patency of the body lumen.

There is described zeolites containing releasably adsorbed nitric oxide, methods of preparing the zeolites, methods of releasing the nitric oxide into a solution or into air and uses of the zeolites in therapy.

Disclosed are metal organic frameworks that adsorb nitric oxide, NO-loaded metal organic frameworks, methods of preparing the NO-loaded metal organic frameworks, methods of releasing the nitric oxide into a solution or into air, and uses of the metal organic frameworks.

There is described zeolites containing releasably adsorbed nitric oxide, methods of preparing the zeolites, methods of releasing the nitric oxide into a solution or into air and uses of the zeolites in therapy.

A dual-layer bag catheter is composed of two ball layers and three cavities. Its internal bag layer is used for expanding blood vessel. Its external bag layer made of unique millipore film is used for delivering the therapeutic genes or medicine to the wall of blood vessel or target organ.

A method for manufacturing a helical stent includes the steps of providing a stent body with struts disposed about the circumference thereof in turns and with bridges connecting the struts in adjacent turns. The stent body is at least partially expanded and, some time during expansion, some of the bridges, in particular, sacrificial bridges, are removed. A method for implanting this stent includes loading the stent at a stent delivery system, traversing the stent at the delivery system to an implantation site, and implanting the stent at the implantation site.

A medical device comprising a supporting structure capable of including or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may include one or more therapeutic agents or substances, with the carrier including a coating on the surface thereof, and the coating including the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

A stent includes a stent body having a circumference and struts disposed helically about the circumference. Each of the struts has a strut length and a ratio of a number of the struts around the circumference to the strut length is greater than 800 per inch, in particular, over 1000 per inch. A method for manufacturing a helical stent includes the steps of providing a stent body with struts disposed about the circumference thereof in turns and with bridges connecting the struts in adjacent turns. The stent body is expanded and, thereafter, some of the bridges, in particular, sacrificial bridges, are removed.

A medical device comprising a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to, This drug can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

A stent includes a stent body with a diameter of between approximately 4 and 12 mm and a length of between approximately 10 and 250 mm. S-shaped struts are disposed helically about the circumference along helical turns. The struts have straight portions and curved portions connecting respectively adjacent ones of the straight portions. Bridges connect the struts in adjacent ones of the turns. The bridges include connecting bridges and a given number of sacrificial bridges before being expanded, and the connecting bridges and less than the given number of the sacrificial bridges after being at least partially expanded. A method for manufacturing a helical stent includes the steps of providing a stent body with struts disposed about the circumference thereof in turns and with bridges connecting the struts in adjacent turns. The stent body is expanded and, thereafter, some of the bridges, in particular, sacrificial bridges, are removed.

A stent includes a stent body having a circumference, a diameter of between approximately 4 mm and approximately 12 mm, in particular, 8 mm, and a length of between approximately 10 mm and approximately 250 mm, in particular, 150 mm, and struts disposed helically about the circumference in turns. Substantially circumferentially oriented connecting bridges connect respectively adjacent ones of the turns. A method for manufacturing a helical stent includes the steps of providing a stent body with struts disposed about the circumference thereof in turns and with bridges connecting the struts in adjacent turns. The stent body is expanded and, thereafter, some of the bridges, in particular, sacrificial bridges, are removed.

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent / medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and / or preventing adjacent diseases or maintaining patency of the body lumen.

The present invention provides methods and devices for placement of a stent in a bifurcation or ostial lesion. The stent comprises a main body and a flaring portion. The main body is designed to expand and support a main vessel while the flaring portion deploys at least partially in response to expansion of the main body and is designed to open into and support a side branch or bifurcation ostium area. The stent may also comprise a therapeutic agent which can be delivered to a blood vessel.

Segmented scaffolds composed of disconnected scaffold segments are disclosed. System of and methods for delivery of the segmented scaffolds are disclosed.

The invention provides a preparation method of polyester drug-eluting coating intravascular stent. The method comprises the steps of the cleaning of the intravascular stent, the preparation of a coating solution, the coating of drug-eluting coating, the drying and disinfecting processes of drug-eluting coating, etc. The preparation method selects the polyester, which can be degraded into carbon dioxide and water in the human body in 3 to 6 months, metabolized by the human body and finally excreted out, as a polymer drug carrier. By adopting the polymer drug carrier, the stent with the coating can not only reduce the occurrence of restenosis, but also effectively reduce the occurrence of subacute thrombosis and hemangioma afterstent implantation, and guarantee the long-term clinic safety and efficiency after stent implantation. The polymer carrier with antiproliferative drugs is coated on the outer surface of the stent to achieve the function of reducing the intimal hyperplasia at one side of blood vessels and tissues. Meanwhile, fewer drugs are carried at the side facing to the blood vessel cavity to facilitate the curing of endothelium.

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity.